CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 14, 2021—Grail introduced its Galleri multicancer early detection blood test, intended for use in people with an elevated risk of cancer, such as adults aged 50 or older, and as a complement to single-cancer screening tests.
In an observational study, the test demonstrated the ability to detect more than 50 types of cancer, of which more than 45 lack recommended screening tests in the United States, with a low false-positive rate of less than one percent. When cancer is detected, the Galleri test can determine the cancer signal origin with high accuracy. Data from the Circulating Cell-free Genome Atlas study published in Clinical Cancer Research (Chen X, et al. Online ahead of print June 4, 2021) demonstrated the ability of the company’s technology to preferentially detect cancers that are more aggressive than expected based on age, cancer stage, and cancer type.